Posted by Michael Wonder on 17 Dec 2020
ICER publishes final evidence report and policy recommendations on new therapies for bladder cancer
17 December 2020 - Independent appraisal committee determines current evidence is adequate to demonstrate that nadofaragene firadenovec and oportuzumab monatox provide a net health benefit over best supportive care, but that the evidence is inadequate to enable a clear comparison of these treatments to each other or to other active treatments.
The Institute for Clinical and Economic Review today released a Final Evidence Report and Report-at-a-Glance assessing the comparative clinical effectiveness and value of nadofaragene firadenovec (Adstiladrin, FKD Therapies Oy and FerGene) and oportuzumab monatox (Vicineum, Sesen Bio) for the treatment of non-muscle invasive bladder cancer that is unresponsive to Bacillus Calmette-Guerin intravesical therapy.
